CINCA

Please read these Terms of Use and Privacy Statement (collectively, the "Terms") carefully before using any of the box above indicates that you accept these Terms.

Are you interested in exploring ongoing clinical trials for CINCA at the University of Alabama at Birmingham?

Yes

Following specialists treat CINCA. Help us improve our data based on your experience.

100%

0%20%40%60%80%

Specialty scores for CINCA

Overview

Cryopyrin-associated periodic syndrome

medical Products

Ilaris

Trade Name: Canakinumab

Indication: Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older. Also approved for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.

FDA Approved Medicines

FDA approved canakinumab, sold as Ilaris, manufactured by Novartis for the treatment of Cryopyrin-Associated Periodic Syndromes ( CINCA ) in year 2009.